Company intelligence / Profile preview

Shenzhen Rui Therapeutics

Shenzhen, Guangdong, China

Ownership: Private
Development stage: Other

Overview

Rui Therapeutics is a Shenzhen-based biotechnology company specializing in the development of next-generation targeted protein degradation (TPD) therapies. The company leverages its proprietary platform to design molecular glues and PROTACs aimed at previously undruggable targets in oncology and immunology. By focusing on the degradation of disease-causing proteins rather than simple inhibition, Rui Therapeutics seeks to overcome resistance mechanisms common in traditional small molecule treatments. The company is currently advancing a pipeline of pre-clinical candidates through early-stage discovery and optimization.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeMolecular glue therapyProteolysis-targeting chimera therapy
Industry: Biotech

Beyond the preview

Go deeper on Shenzhen Rui Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenzhen Rui Therapeutics.

Explore the full profile